Javier Chaparro‐Riggers

Pfizer (United States) — United States

Medicine · Health Sciences

29h-index3.9kcitations137works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(62), Biosimilars and Bioanalytical Methods(43), Monoclonal and Polyclonal Antibodies Research(41), Multiple Myeloma Research and Treatments(21), Synthesis and Biological Evaluation(17)

Publications137 total

Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Data from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Supplementary Table from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2025Open Access
Nanomechanical binding mechanism of ligands drives agonistic activity
Nature Communications·2025Open Access
Structural elucidation of the haptoglobin–hemoglobin clearance mechanism by macrophage scavenger receptor CD163
PLoS Biology·2025· 2 citedOpen Access
Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4
2025Open Access
Abstract 3414: PD-1 targeting increases the tolerance of IL-12 while maintaining potent anti-tumor immunity
Cancer Research·2025
Structural elucidation of the haptoglobin–hemoglobin clearance mechanism by macrophage scavenger receptor CD163
2025Open Access
Epitope Mapping Using Yeast Display and Next Generation Sequencing
Methods in molecular biology·2025
Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys.
Journal of Clinical Oncology·2024
Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab.
Journal of Clinical Oncology·2024· 2 cited
Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys
PLoS ONE·2024· 5 citedOpen Access
Increased FAN1 expression by mRNA-LNP attenuates CAG repeat expansion in Huntington patients’ iPSC-derived astrocytes
2023· 4 citedOpen Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2023Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2023Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2023Open Access
Supplementary Figure from Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Kevin C. Lindquist(17), Thomas Van Blarcom(15), Arvind Rajpal(14), Pavel Strop(13), Barbra J. Sasu(12), Yik A. Yeung(11), Sherman M. Chin(9), Janette Sutton(8), Zea Melton(8), Edward Pascua(7), Yasmina Abdiche(6), Jaume Pons(6), Karen M. Polizzi(6), Andreas S. Bommarius(6), Andrea Rossi(6), Jaume Pons(6), Cesar Sommer(6), Tao Sai(6), David L. Shelton(5), Bijan Boldajipour(5)